Samina Hamied stepping down as Cipla VC not part of any stake sale plan: Exclusive

"The move is part of the larger strategy laid out by the promoters towards a Cipla that is fully professionally managed. Ms. Hamied’s role as a part of the promoter family was to guide Cipla onto its future course and set in place a robust management team that could drive it in the long-term, which is reflected in the company’s strong performance over the recent years," said Cipla's official statement in response to CNBC-TV18's story.

Promoters of India's third-largest generic drug company by revenue currently own 33.47% stake in the company as of December 31, 2023.

CNBC-TV18 had reported last year that Torrent Pharma is likely to have entered the fray to acquire the Hamied family's stake in Cipla.

In an interaction with the CNBC-TV18 in November last year, Cipla's global CEO Umang Vohra had mentioned that they are not part of any transaction yet.

"The company doesn't comment on it, the promoters have not commented on it. We respond to what we do as a company through various statutory announcements, there have been none. As of two days back, we also opened the window for our employees. So I think people could infer, based on all of this, seems like it's business as usual," he had said back then.

For the December quarter, Cipla reported US business sales in excess of $200 million for the fourth quarter in a row. CEO Vohra said that $220 million to $225 million would be a normalised base for the US business.

He expects full-year margins for Cipla to be around 24% and while remediation process is on for its Indore facility, he has not heard back from the USFDA yet.

The drugmaker's shares ended 3% lower on Thursday and have risen 17% over the last six months.